

ORIGINAL ARTICLE

Pattern of allergic rhinitis at a tertiary care hospital

Deepak Ahlawat¹, Shalini Chandra², Abhinav Srivastava³

¹Department of ENT, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India, ²Professor and Head, Department of Pharmacology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India, ³Professor and Head, Department of ENT, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India

Corresponding Author:

Dr. Abhinav Srivastava, Department of ENT, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India. E-mail: drabhinavsrivastava7@ gmail.com

Received: 29-09-2022 Accepted: 14-10-2022

How to cite this article: Ahlawat D, Chandra S, Srivastava A. Pattern of allergic rhinitis at a tertiary care hospital. Int J Adv Integ Med Sci 2023;8(1):1-4.

Source of Support: Nil, Conflicts of Interest: None declared.

INTRODUCTION

When an allergen is exposed, IgE-mediated inflammation results, resulting in allergic rhinitis, an inflammatory condition of the nasal mucosa. Sneezing, rhinorrhea, nasal irritation, and nasal congestion are its four primary clinical signs. Asthma, atopic dermatitis, and nasal polyps are a few other disorders that it may be linked to. In India, allergic rhinitis affects 20–30% of the population.^[11] It is a highly predominant disorder and a major source of discomfort to the patients. The clinical symptoms of patient suffering from allergic rhinitis can decrease patient routine work, sleep, school performance, and overall decrease quality of life. Allergic rhinitis is associated with inflammation in the nasal mucosa along with the epithelial accumulation of

Access this article online	
Website: www.ijaims.in	Quick Response code

Introduction: When an allergen is exposed, IgE-mediated inflammation results, resulting in allergic rhinitis, an inflammatory condition of the nasal mucosa. Sneezing, rhinorrhea, nasal irritation, and nasal congestion are its four primary clinical signs. In India, allergic rhinitis affects 20-30% of the population. **Materials and Methodology:** The present study has been performed to study the sociodemographic profile of the patients with Allergic Rhinitis of either gender between the age of 18–60 years at a tertiary care teaching institution from November 1, 2020, to October 31, 2021. **Observation and Results:** The youngest was 18 years and the eldest was 60 years with 21-30 years as the most common affected age group with female preponderance. The pattern of presentation was perennial with monsoon and winter as the most affected seasons. The mean total scorer for allergic rhinitis was 5 ± 1.2 . **Conclusion:** Allergic rhinitis is the commonest immunologic disease and is the commonest chronic disease experienced by humans. It affects both the sexes and all the age groups.

KEY WORDS: Allergic rhinitis, Score for allergic rhinitis, Seasonal versus Perennial

effector cells that are basophils and mast cells. These effector cells are activated by antigen antibody reaction, thereby inducing the secretion of both newly generated and preformed mediators.^[2]

Allergic rhinitis was earlier subdivided, based on time of exposure, into seasonal, and perennial. This subdivision was not completely satisfactory. The recent classification of the allergic rhinitis disorder as proposed by allergic rhinitis and also its impact on asthma guidelines is on the foundation of: Duration as "intermittent" or "persistent" disease, severity of symptoms and also quality of life as "mild" or "moderate-severe."

When a previously sensitized individual produces an adverse response to a foreign chemical or to physical condition that individual is said to have an allergy. Histamine is now recognized to alter chronic inflammation and to regulate a number of crucial events in the immune response, despite first being thought of as a mediator of acute inflammatory and rapid hypersensitivity reactions. Histamine has a role in a variety of processes, including cell division, differentiation, hematopoiesis, embryonic development, memory and cognition, sleep-wake cycles, gastric acid secretion, and energy and endocrine balance. Histamine

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creative commons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

causes the pathophysiological changes that underlie the symptoms, including vasodilatation, increased vascular permeability, hypotension, bronchoconstriction, and stimulation of airway vagal afferent nerves, through the H1 receptor. These pathophysiological changes include pruritus, pain, flushing, and dyspnea.

Management of the allergic rhinitis is lifelong and revolves around allergen avoidance, along with verity of drugs alone or in combination such as short-term decongestants and oral steroid, longterm intranasal corticosteroids, and topical or oral antihistamines.

MATERIALS AND METHODS

The present study has been performed to study the sociodemographic profile of the patients with Allergic Rhinitis of either gender between the ages of 18–60 years at a tertiary care teaching institution in western Uttar Pradesh for a period of 1 year from November 1, 2020, to October 31, 2021. An ethical clearance was obtained from the Institutional Ethical Committee before starting the study.

To conclude the prevalence of allergic rhinitis in our study population, the score for allergic rhinitis (SFAR) was used. The SFAR include eight components, which are as follows:^[3]

- (1) Nasal symptoms in the past 1 year, including runny nose, sneezing, and blocked nose
- (2) Nasal symptoms supplemented with itchy-watery eyes (rhinoconjuctivitis)
- (3) Month of the year in which the nasal symptoms have occur
- (4) Triggers for the nasal symptoms, including pollens and house dust
- (5) Apparent allergic status
- (6) Preceding medical diagnosis of allergy
- (7) Preceding positive tests of allergy; and
- (8) Familial history of allergy if any.

The total nasal symptom score (TNSS) was used to assess the allergic rhinitis. The TNSS involves five components, including the following:^[4]

- 1. Please rate how your nasal congestion has been over the past: Mild, moderate, and severe
- 2. Please rate how your runny nose has been over the past: Mild, moderate, and severe
- 3. Please rate how your nasal itching has been over the past: Mild, moderate, and severe
- 4. Please rate how your sneezing has been over the past: Mild, moderate, and severe
- 5. Please rate how difficult sleep has been with nasal symptoms: Mild, moderate, and severe

OBSERVATION AND RESULTS

Age Group Distribution

In our study, age of patients was in range from 18 to 60 years. The youngest was 18 years and the eldest was 60 years [Table 1].

Gender Distribution

In our study, out of 140 cases in 48.6% were male and 51.4% were female [Figure 1].

Income Distribution

Out of 140 cases, majority 62 (65.7%) patients belonged to lowincome category followed by middle-income category 42 (30%) cases and with only 6 (4.3%) cases in high-income category [Figure 2].

Duration of Presentation

Out of 140 cases, maximum 66 (47.1%) of patients with allergic rhinitis were presenting them symptoms duration was 6 months to 1 months followed by 41.4% of <6 months and 11.4% in >1 year [Table 2].

Seasonal Versus Perennial

Table 1: Age group		
Age groups (years)	Allergic rhinitis, n (%)	
≤20	29 (20.7)	
21–30	52 (37.1)	
31-40	26 (18.6)	
41–50	15 (10.7)	
51-60	18 (12.9)	
Total	140	




Figure 1: Gender distribution




Figure 2: Income

Maximum cases were seasonal allergic rhinitis presentation with 115 (82.1%) and 25 (17.9%) with perennial allergic rhinitis [Table 3].

Season Wise Distribution

Out of 140 cases, maximum 56 (40%) of patients of seasonal allergic rhinitis presented during monsoon season, followed by winter with 54 (38.6%) cases and rest 30 (21.4%) cases in summers [Table 4].

Family History

A total of 33 (23.6%) patients had positive family history.

Mean Total SFAR

Mean total SFAR was 5.0 ± 1.2 in patients of allergic rhinitis [Table 5].

TNSS

In total nasal symptom score, sneezing has the highest score of 2.25 ± 0.5 , followed by runny nose with 2.0 ± 0.8 and difficulty in sleeping had the least score of 1.2 ± 0.8 [Table 6].

DISCUSSION

The age of patients was in the range from 18 to 60 years. The youngest was 18 years and the eldest was 60 years. Maximum number of cases was in between 21 and 30 years 52 (37.1%) [Table 1].

The findings were in accordance with the study done by Van Adelsberg *et al.*,^[5] Ratner *et al.*,^[6] Torvi *et al.*,^[7] and Berger *et al.*,^[4] The possible reason as to why this age group is most effected is the lifestyle and activity which increases the chances of bringing them into contact with a wide variety of allergens as compared to the older age group.

Ellis *et al.*^[8] found female preponderance with male 41% and female 59%, similar result was seen by the study done by Ratner *et al.*^[6] who found male affected with allergic rhinitis in 37.1% and female 62.9%. Allergic rhinitis does not differ in its presentation and clinical course between males and females. Hence, this difference in sex does not affect the comparison of groups, who were selected after randomization [Figure 1].

The present study found that majority 62 (65.7%) subjects belonged to low-income category followed by middle-income category 42 (30%) [Figure 2]. Our findings were found to be in accordance with the study done by LaForce *et al.*,^[1] Hore *et al.*,^[9] and Lee *et al.*,^[10] Although the allergic rhinitis is seen more among high class group, in our study, it was found to affect low socioeconomic group, the probable reason could be that the present study center being a trust hospital caters more of patients of lower socioeconomic strata.

In our study, maximum 66 (47.1%) subjects presented between 6 months and 1 years of symptoms onset and all had seasonal presentation with 78.6% of subjects were symptomatic during monsoon and winter season [Tables 2-4]. Our findings were found to be in accordance with the study done by Torvi *et al.*,^[7] and Berger *et al.*,^[4] who also found increase in symptom of allergic rhinitis during winter and monsoon. In the present study, only 33 (23.6%) subjects had positive family history [Figure 3].

For the diagnosis of allergic rhinitis, SFAR score was used and, in our study mean, total SFAR was found to be 5.0 ± 1.2 . Study done by Elis *et al.*^[4] found a mean total score of 4.7 ± 1.35 in the patients of allergic rhinitis and was found to be effective in diagnosing the disease. Sneezing and runny nose were the most common symptoms [Tables 5 and 6].

Table 2: Duration of presentation	
Duration	n (%)
<6 months	58 (41.4)
6 months-1 year	66 (47.1)
>1 year	16 (11.4)
Total	140

Tab	Table 3: Seasonal versus perennial	
Туре	n (%)	
Seasonal	115 (82.1)	
Perennial	25 (17.9)	
Total	140	

Table 4: Season wise distribution	
Season	n (%)
Summer	30 (21.4)
Winter	54 (38.6)
Monsoon	56 (40.0)
Total	140 (100.0)

Table 5: Mean total score for allergic rhinitis	
Mean total	Mean±SD
score	
Total SFAR	5.0±1.2

SFAR: Score for allergic rhinitis, SD: Standard deviation

Table 6: Total nasal symptom score	
Symptoms	Score, mean±SD
Nasal congestion	1.35±0.6
Runny nose	2.0±0.8
Nasal itching	$1.85{\pm}0.7$
Sneezing	2.25±0.5
Difficulty sleep	1.2±0.8
SD: Standard deviation	






Figure 3: Number

CONCLUSION

Allergic rhinitis is the commonest immunologic disease and is the commonest chronic disease experienced by humans. It affects both the sexes and all the age groups with more presentation in the younger age group.

REFERENCES

- LaForce C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD, *et al.* Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: A 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181-8.
- Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomized controlled trials. BMJ 1998;317:1624-9.
- 3. Pearlman DS, Grossman J, Meltzer EO. Histamine skin test

reactivity following single and multiple doses of azelastine nasal sprayin patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:258-62.

- Berger W, Hampel F Jr., Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:375-81.
- Van Adelsberg J, Philip G, Menten J, Malice MP, Reiss TF, van Bavel JH. Montelukast, a leukotriene receptor antagonist, improves symptoms of spring seasonal allergic rhinitis: A multicenter, double-blind, placebo-controlled study. Allergy 2002;57:46-7.
- Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W, *et al.* Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81.
- Torvi AD, Soujanya S. A comparative study of efficacy of fexofenadine with chlorpheniramine maleate in allergic rhinitis in the outpatient department of otorhinolaryngology. Nat J Physiol Pharm Pharmacol 2021;11:406-10.
- Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo-controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol 2013;9:16.
- 9. Hore I, Georgalas C, Scadding G. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis-a systematic review of randomized controlled trials. Clin Exp Allergy 2005;35:207-12.
- Lee MS, Pittler MH, Shin BC, Kim JI, Ernst E. Acupuncture for allergic rhinitis: A systematic review. Ann Allergy Asthma Immunol 2009;102:269-79.